Carregant...
miR-187-3p increases gemcitabine sensitivity in breast cancer cells by targeting FGF9 expression
Breast cancer is the most common type of malignancy in women, which remains a significant health concern worldwide. Gemcitabine is a frequently applied anticancer pharmacological agent. However, the efficacy of gemcitabine is limited by chemoresistance. In the present study, a combination of reverse...
Guardat en:
| Publicat a: | Exp Ther Med |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
D.A. Spandidos
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7388565/ https://ncbi.nlm.nih.gov/pubmed/32765654 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2020.8770 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|